Page last updated: 2024-12-04

ciclopirox

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Ciclopirox is an antifungal medication used to treat a variety of fungal infections, including athlete's foot, jock itch, and ringworm. It is available over the counter as a cream, lotion, or spray. Ciclopirox works by inhibiting the growth of fungi. It is synthesized by a multi-step process involving the reaction of 2-hydroxy-4-methyl-5-chlorobenzaldehyde with 4-chlorophenol in the presence of a base. Ciclopirox has been shown to be effective in treating fungal infections, and it is generally well-tolerated. It is studied to understand its mechanism of action, efficacy, and safety in treating various fungal infections. Ciclopirox is an important antifungal medication for its broad-spectrum activity and effectiveness in treating a wide range of fungal infections.'

Cross-References

ID SourceID
PubMed CID2749
CHEMBL ID1413
CHEBI ID453011
SCHEMBL ID34424
MeSH IDM0057995

Synonyms (128)

Synonym
BIDD:GT0080
smr001233223
MLS002153867 ,
29342-05-0
6-cyclohexyl-1-hydroxy-4-methyl-pyridin-2-one
ciclopirox ,
loprox
2(1h)-pyridinone, 6-cyclohexyl-1-hydroxy-4-methyl-
(6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone)
ciclopiroxum [inn-latin]
2(1h)-pyridone, 6-cyclohexyl-1-hydroxy-4-methyl-
terit
cyclopirox
einecs 249-577-2
6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone
penlac
hoe 296b
D03488
ciclopirox (usp/inn)
penlac (tn)
BSPBIO_000581
BSPBIO_002041
BPBIO1_000641
NCGC00178850-02
NCGC00178850-01
SPECTRUM5_000747
PRESTWICK2_000541
PRESTWICK3_000541
6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridinone
DB01188
loprox (tn)
KBIO3_001261
KBIOGR_000816
SPBIO_002502
SPECTRUM4_000288
SPECTRUM2_000146
SPECTRUM3_000351
PRESTWICK0_000541
SPBIO_000252
PRESTWICK1_000541
CHEMBL1413
hoe-296b
6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one
ciclopiroxum
6-cyclohexyl-1-hydroxy-4-methylpyridin-2(1h)-one
chebi:453011 ,
A819878
6-cyclohexyl-4-methyl-1-oxidanyl-pyridin-2-one
6-cyclohexyl-1-hydroxy-4-methyl-2-pyridinone
NCGC00017112-05
NCGC00017112-04
NCGC00017112-06
loprox gel
ciclopirox gel
loprox cream
ciclopirox [usan:usp:inn:ban]
19w019zdrj ,
unii-19w019zdrj
cnl8
ciclopirox olamin
stieprox
ciclopirox-olamin
FT-0602961
NCGC00017112-08
NCGC00017112-11
AB06517
ciclopirox [ep monograph]
ciclopirox [inn]
ciclopirox [mart.]
ciclopirox [mi]
ciclopirox [usan]
ciclopirox [usp monograph]
ciclopirox [vandf]
ciclopirox [usp-rs]
ciclopirox [orange book]
ciclopirox [who-dd]
AKOS015895717
S2528
HY-B0450
SCHEMBL34424
KS-5085
1-hydroxy-4-methyl-6-cyclohexyl-2-pyridone
6-cyclohexyl-1-hydroxy-4-methyl-1h-pyridin-2-one
DTXSID9048564 ,
W-106995
2-azanylethanol;6-cyclohexyl-4-methyl-1-oxidanyl-pyridin-2-one
bdbm66087
cid_38911
2-aminoethanol;6-cyclohexyl-1-hydroxy-4-methyl-2-pyridone
2-aminoethanol;6-cyclohexyl-1-hydroxy-4-methyl-2-pyridinone
AC-24195
6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridinone #
6-cyclohexyl-1-hydroxy-4-methyl-2-(1h)-pyridone
AB00053438_10
AB00053438_09
AB00053438_11
6-cyclohexyl-1-hydroxy-4-methyl-1,2-dihydropyridin-2-one
hoe296b
SR-05000001589-5
HMS3656I12
ciclopirox; 6-cyclohexyl-1-hydroxy-4-methylpyridin-2(1h)-one
SBI-0206690.P002
mfcd00599441
ciclopirox, >=98% (hplc)
ciclopirox, european pharmacopoeia (ep) reference standard
ciclopirox, united states pharmacopeia (usp) reference standard
SW196923-5
Q419468
Z1509504366
ciclopirox (penlac)
hoe 296; hoe-296;ciclopiroxum; penlac
BCP28530
BRD-K13044802-213-09-0
BRD-K13044802-213-04-1
CCG-266632
29342-05-0 (free)
ciclodan
gtpl11349
EN300-197928
ciclopirox (usp monograph)
ciclopirox (mart.)
d01ae14
ciclopirox (ep monograph)
dtxcid2028193
g01ax12
ciclopirox (usp-rs)
ciclopiroxum (inn-latin)
ciclopirox (usan:usp:inn:ban)

Research Excerpts

Overview

Ciclopirox (CPX) is a broad-spectrum antimycotic agent which also exerts anti-inflammatory effects in human diseases. It is an FDA-approved topical antifungal agent that has demonstrated preclinical anticancer activity in a number of solid and hematologic malignancies.

ExcerptReferenceRelevance
"Ciclopirox (CPX) is a broad-spectrum antimycotic agent which also exerts anti-inflammatory effects in human diseases."( Ciclopirox mitigates inflammatory response in LPS-induced septic shock via inactivation of SORT1-mediated wnt/β-Catenin signaling pathway.
Chen, J; Deng, Y; He, Y; Li, X; Wang, W; Zhou, L, 2023
)
3.07
"Ciclopirox olamine (CPO) is a topical wide-spectrum antimycotic agent that possesses antifungal, antibacterial and anti-inflammatory activities. "( Formulation and Evaluation of Novel Hybridized Nanovesicles for Enhancing Buccal Delivery of Ciclopirox Olamine.
AbouSamra, MM; Awad, GEA; Mansy, SS; Salama, AH, 2020
)
2.22
"Ciclopirox (CPX) is an antifungal drug that has recently been reported to act as a potential anticancer drug. "( Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK/p38 MAPK and NF-κB signaling.
Cai, L; Chen, L; Han, S; Jin, Q; Li, Q; Liu, Y; Lu, B; Lu, J; Shangguan, F; Su, Z; Tian, X; Wang, C; Wang, L; Yu, S; Zheng, W; Zhou, N, 2021
)
3.51
"Ciclopirox (CPX) is an FDA-approved topical antifungal agent that has demonstrated preclinical anticancer activity in a number of solid and hematologic malignancies. "( Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting the γ-secretase complex.
Anant, S; Baltezor, MJ; Bhattacharyya, S; Brinker, AE; Dalton, M; Dandawate, P; Ham, T; Jensen, RA; McCulloch, W; Ramamoorthy, P; Rangarajan, P; Reed, GA; Standing, D; Tanol, M; Taylor, JA; Weir, SJ; Wood, R; Woolbright, BL, 2021
)
2.69
"Ciclopirox (CPX) is a synthetic antifungal drug that is mainly used to treat dermatomycoses. "( Combined analysis of gene expression and genome binding profiles identified potential therapeutic targets of ciclopirox in Ewing sarcoma.
Ji, W; Li, J; Xia, H; Yuan, B, 2018
)
2.14
"Ciclopirox olamine (CPX) is an antifungal drug that has been reported to have antitumor effects. "( Antileukemia Effect of Ciclopirox Olamine Is Mediated by Downregulation of Intracellular Ferritin and Inhibition β-Catenin-c-Myc Signaling Pathway in Glucocorticoid Resistant T-ALL Cell Lines.
Gao, J; Gu, L; Liu, H; Ma, Z; Wei, Y; Wu, J; Zhang, G; Zhang, Y, 2016
)
2.19
"Ciclopirox is a synthetic antimycotic agent available in a variety of formulations to treat superficial fungal infections. "( Ototoxic effect of topical ciclopirox as an antimycotic preparation.
Akdaş, F; Baylancicek, S; Ciprut, A; Sari, M; Serin, GM; Tutkun, A, 2008
)
2.09
"Ciclopirox olamine (CPX) is a synthetic antifungal agent clinically used to treat mycoses of the skin and nails. "( The antitumor activity of the fungicide ciclopirox.
Chen, W; Han, X; Huang, S; Liu, L; Luo, Y; Pang, J; Rivera, CA; Shen, T; Xu, B; Zhou, H, 2010
)
2.07
"Ciclopirox is a topical antimycotic agent belonging to the chemical class of hydroxypyridones and not related to azoles or any other class of antifungal agents. "( Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent.
Mailland, F; Monti, D; Subissi, A; Togni, G, 2010
)
3.25
"Ciclopirox olamine is a synthetic antifungal agent with a high affinity for trivalent metal cations. "( The possible mechanism of action of ciclopirox olamine in the yeast Saccharomyces cerevisiae.
Chae, JY; Kim, IS; Leem, SH; Park, JE; Sugino, A; Sunwoo, Y, 2003
)
2.04
"Ciclopirox is a broad-spectrum antifungal agent that also exhibits anti-inflammatory and antibacterial activity. "( Ciclopirox for the treatment of superficial fungal infections: a review.
Gupta, AK; Skinner, AR, 2003
)
3.2
"Ciclopirox (Loprox) gel is a hydroxypyridone, broad-spectrum antifungal agent proven effective against the yeast M."( Ciclopirox gel for seborrheic dermatitis of the scalp.
Aly, R; Katz, HI; Kempers, SE; Lookingbill, DP; Lowe, N; Menter, A; Morman, M; Savin, RC; Wortzman, M, 2003
)
2.48
"Ciclopirox is a broad-spectrum, hydroxypyridone-derived, synthetic antifungal agent with anti-inflammatory properties."( Efficacy of different concentrations of ciclopirox shampoo for the treatment of seborrheic dermatitis of the scalp: results of a randomized, double-blind, vehicle-controlled trial.
Altmeyer, P; Hoffmann, K, 2004
)
1.31
"Ciclopirox is a broad-spectrum, hydroxypyridone-derived, synthetic antifungal agent with anti-inflammatory properties."( Rationale of frequency of use of ciclopirox 1% shampoo in the treatment of seborrheic dermatitis: results of a double-blind, placebo-controlled study comparing the efficacy of once, twice, and three times weekly usage.
Abeck, D, 2004
)
1.33
"Ciclopirox is a synthetic, hydroxypyridone-derived, broad-spectrum antifungal agent with anti-inflammatory properties."( Safety and efficacy of ciclopirox 1% shampoo for the treatment of seborrheic dermatitis of the scalp in the US population: results of a double-blind, vehicle-controlled trial.
Lebwohl, M; Plott, T, 2004
)
1.36
"Ciclopirox (Loprox) is a broad-spectrum antifungal medication that also has antibacterial and anti-inflammatory properties. "( Ciclopirox (Loprox) gel for superficial fungal infections.
Bluhm, R; Gupta, AK,
)
3.02
"Ciclopirox is a broad-spectrum antifungal, antibacterial, and anti-inflammatory agent. "( A multicenter, open-label study to assess the safety and efficacy of ciclopirox topical suspension 0.77% in the treatment of diaper dermatitis due to Candida albicans.
Gallup, E; Plott, T,
)
1.81
"Ciclopirox is a topical antifungal agent of the hydroxypyridone class whose mode of action is poorly understood. "( Oxygen accessibility and iron levels are critical factors for the antifungal action of ciclopirox against Candida albicans.
Hube, B; Korting, HC; Niewerth, M; Schäfer-Korting, M; Sigle, HC; Thewes, S, 2005
)
1.99
"Ciclopirox olamine is a synthetic hydroxypiridone derived, broad spectrum, antifungal agent which has been used effectively to treat seborrheic dermatitis. "( The safety and efficacy of ciclopirox olamine for the treatment of seborrheic dermatitis.
Aly, R; Starova, A, 2005
)
2.07
"Ciclopirox is an antifungal agent and is effective against both Gram-positive and Gram-negative bacteria. "( Evaluation of the efficacy of ciclopirox 0.77% gel in the treatment of tinea pedis interdigitalis (dermatophytosis complex) in a randomized, double-blind, placebo-controlled trial.
Cooper, EA; Gupta, AK; Skinner, AR, 2005
)
2.06
"Ciclopirox is a broad-spectrum, hydroxypyridone-derived, synthetic antifungal agent, which also has anti-inflammatory properties."( Ciclopirox 1% shampoo for the treatment of seborrheic dermatitis.
Gupta, AK; Nicol, KA, 2006
)
2.5
"Ciclopirox olamine (CPO) is a broad-spectrum antifungal with anti-inflammatory properties effective against the yeast implicated in seborrhoeic dermatitis, Malassezia spp. "( Clinical efficacies of shampoos containing ciclopirox olamine (1.5%) and ketoconazole (2.0%) in the treatment of seborrhoeic dermatitis.
Boorman, GC; Ratnavel, RC; Squire, RA, 2007
)
2.05
"Ciclopirox is a synthetic hydroxypyridone antifungal agent. "( Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis.
Bohn, M; Kraemer, KT, 2000
)
2.06
"Ciclopiroxolamine is a broad-spectrum antimycotic drug. "( Micro-liquid chromatography method for the determination of ciclopiroxolamine after pre-column derivatization in topical formulations.
Belliardo, F; Bertolino, A; Brandolo, G; Lucarelli, C, 1991
)
1.97
"The ciclopiroxolamine is a new synthetic antifungal agent related to pyridones; it is the ethanolamine salt of the pyridone acid 6-cyclohexyl 1-hydroxy 4-methyl 2 (1H). "( [In vitro antifungal spectrum of ciclopiroxolamine].
Goudard, M; Lubrano, N; Regli, P, 1989
)
1.12
"Ciclopirox olamine is a substituted pyridone antimycotic, unrelated to the imidazole derivatives, with activity against a broad spectrum of dermatophytes, yeasts, actinomycetes, molds, other fungi, and a variety of Gram-positive and Gram-negative bacteria. "( Ciclopirox olamine 1% cream. A preliminary review of its antimicrobial activity and therapeutic use.
Brogden, RN; Dawson, GW; Jue, SG, 1985
)
3.15

Effects

The ciclopirox olamine (CPO) has a broad antimicrobial profile including dermatophytes, yeasts and is used in various pharmaceutical forms. It has the potential to be repurposed as a cytoprotective and anti-inflammatory agent.

ExcerptReferenceRelevance
"The ciclopirox olamine (CPO) has a broad antimicrobial profile including dermatophytes, yeasts and is used in various pharmaceutical forms. "( MODELLING AND BIOPHARMACEUTICAL EVALUATION OF CICLOPIROX OLAMINE GELS.
Askiene, MI; Briedis, V; Grigonis, A; Mazurkeviciute, A; Ramanauskiene, K, 2017
)
1.27
"Ciclopirox has the potential to be repurposed as a cytoprotective and anti-inflammatory agent."( High-content screening identifies inhibitors of oxidative stress-induced parthanatos: cytoprotective and anti-inflammatory effects of ciclopirox.
Bakondi, E; Demény, MA; Hajnády, Z; Hegedűs, C; Kiss, A; Kovács, K; Nagy-Pénzes, M; Regdon, Z; Virág, L, 2021
)
1.55
"The ciclopirox olamine (CPO) has a broad antimicrobial profile including dermatophytes, yeasts and is used in various pharmaceutical forms. "( MODELLING AND BIOPHARMACEUTICAL EVALUATION OF CICLOPIROX OLAMINE GELS.
Askiene, MI; Briedis, V; Grigonis, A; Mazurkeviciute, A; Ramanauskiene, K, 2017
)
1.27
"Ciclopirox (CPX) has been used as an antifungal agent in various formulations to treat superficial fungal infection for decades. "( Repositioning the Old Fungicide Ciclopirox for New Medical Uses.
Huang, S; Shen, T, 2016
)
2.16
"Ciclopirox has demonstrated both fungicidal and fungistatic activity in vitro against a broad spectrum of pathogenic fungi."( Ototoxic effect of topical ciclopirox as an antimycotic preparation.
Akdaş, F; Baylancicek, S; Ciprut, A; Sari, M; Serin, GM; Tutkun, A, 2008
)
1.36
"Ciclopirox has been experimentally used as a cell cycle G1/S phase transition blocker (Hoffman et al., Cytometry 12 (1991) 26)."( Ciclopirox prevents peroxynitrite toxicity in astrocytes by maintaining their mitochondrial function: a novel mechanism for cytoprotection by ciclopirox.
Choi, JJ; Kim, HC; Kim, WK; Ko, KH; Kong, MY; Lee, SJ, 2002
)
2.48
"Ciclopirox has been formulated in a nail lacquer delivery system."( Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis.
Bohn, M; Kraemer, KT, 2000
)
1.34

Actions

ExcerptReferenceRelevance
"Ciclopirox also displays mild anti-inflammatory effects in biochemical and pharmacological models; effects also shown in small clinical studies."( Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent.
Mailland, F; Monti, D; Subissi, A; Togni, G, 2010
)
2.52

Treatment

Treatment with ciclopirox nail lacquer for onychomycosis has a favorable risk-benefit ratio. Treatment did not directly cause cell membrane damage and did not change intracellular levels of ATP.

ExcerptReferenceRelevance
"Ciclopiroxolamine treatment showed an equivalent effectiveness to that of clotrimazole both on signs and symptoms and on vaginal smear culture."( [A clinical study of cyclopyroxolamine versus clotrimazole in the treatment of mycotic vulvovaginitis].
Giannoni, M; Jacobellis, M; Pollastro, M,
)
0.85
"Treatment with ciclopiroxolamine reduced the sum score of the clinical signs of seborrheic dermatitis to a greater extent than the vehicle (p ( Ciclopiroxolamine cream for treating seborrheic dermatitis: a double-blind parallel group comparison.
Korting, HC; Nicholls, D; Nietsch, KH; Schinzel, S; Ulbricht, H; Unholzer, A; Varigos, G, 2002
)
2.1
"Treatment with ciclopirox did not directly cause cell membrane damage and did not change intracellular levels of ATP."( Oxygen accessibility and iron levels are critical factors for the antifungal action of ciclopirox against Candida albicans.
Hube, B; Korting, HC; Niewerth, M; Schäfer-Korting, M; Sigle, HC; Thewes, S, 2005
)
0.89
"Treatment with ciclopirox nail lacquer for onychomycosis has a favorable risk-benefit ratio."( Ciclopirox nail lacquer: a brush with onychomycosis.
Gupta, AK, 2001
)
2.09
"Treatment with ciclopirox nail lacquer reduced the mean affected nail area from 64.3% at baseline to 41.2% at 3 months and 25.7% at 6 months."( A multicenter, open-label study of the efficacy and safety of ciclopirox nail lacquer solution 8% for the treatment of onychomycosis in patients with diabetes.
Nietsch, KH; Seebacher, C; Ulbricht, HM, 2001
)
0.89
"Treatment with ciclopirox olamine cream 1% was applied topically twice daily."( [Experience in the treatment of skin mycoses with ciclopirox olamine].
Lecha Carralero, V; Martínez Tomás, C, 1989
)
0.87

Toxicity

Ciclopirox shampoo 1% is effective and safe in the treatment of seborrheic dermatitis of the scalp. Terbinafine pulse therapy is an effective alternative in treatment of onychomycosis due to dermatophytes.

ExcerptReferenceRelevance
" Adverse events were mild to moderate, with no serious events reported."( A multicenter, open-label study of the efficacy and safety of ciclopirox nail lacquer solution 8% for the treatment of onychomycosis in patients with diabetes.
Nietsch, KH; Seebacher, C; Ulbricht, HM, 2001
)
0.55
" The majority of subjects experienced adverse events that were mild in intensity, with skin and appendage reactions the most commonly reported, at similar frequency in both groups."( Safety and efficacy of ciclopirox 1% shampoo for the treatment of seborrheic dermatitis of the scalp in the US population: results of a double-blind, vehicle-controlled trial.
Lebwohl, M; Plott, T, 2004
)
0.63
"Ciclopirox shampoo 1% is effective and safe in the treatment of seborrheic dermatitis of the scalp."( Safety and efficacy of ciclopirox 1% shampoo for the treatment of seborrheic dermatitis of the scalp in the US population: results of a double-blind, vehicle-controlled trial.
Lebwohl, M; Plott, T, 2004
)
2.08
" Safety and efficacy variables included adverse events, mycological culture studies, KOH tests, Severity Scores, and Global Evaluation of Clinical Response."( A multicenter, open-label study to assess the safety and efficacy of ciclopirox topical suspension 0.77% in the treatment of diaper dermatitis due to Candida albicans.
Gallup, E; Plott, T,
)
0.37
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
"Terbinafine pulse therapy is effective and safe alternative in treatment of onychomycosis due to dermatophytes; and combination therapy with topical ciclopirox or amorolfine do not show any significant difference in efficacy in comparison to monotherapy with oral terbinafine."( An open randomized comparative study to test the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in the treatment of onychomycosis.
Garg, AP; Jaiswal, A; Sharma, RP,
)
0.53
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" No adverse events were reported in 62% of the patients."( [Phase III study of the efficacy and safety of ciclopirox olamine cream in small children with dermatomycosis].
Crespo Erchiga, V; Gómez-Moyano, E; González Enseñat, MA; Hiraldo Gamero, A; Moreno Giménez, JC; Vera Casaño, Á; Vicente Villa, MA; Zsolt Fradera, I,
)
0.39
"Ciclopirox olamine cream 1% is a safe and feasible treatment for superficial cutaneous mycotic infections, especially Candida spp."( [Phase III study of the efficacy and safety of ciclopirox olamine cream in small children with dermatomycosis].
Crespo Erchiga, V; Gómez-Moyano, E; González Enseñat, MA; Hiraldo Gamero, A; Moreno Giménez, JC; Vera Casaño, Á; Vicente Villa, MA; Zsolt Fradera, I,
)
1.83
" There are limited data on adverse events associated with the newer topical onychomycosis drugs."( Retrospective analysis of adverse events with topical onychomycosis medications reported to the United States Food and Drug Administration.
Lipner, SR; Wang, Y, 2020
)
0.56

Pharmacokinetics

The aim of this work was to evaluate the pharmacokinetic parameters of ciclopirox olamine after the buccal application of mucoadhesive film prepared by the solvent casting method.

ExcerptReferenceRelevance
" The DPK data observed indicate a higher Cmax value (175."( Skin uptake and clearance of ciclopirox following topical application.
Al-Dhubiab, BE; Alhaider, IA; Attimarad, M; Harsha, S; Nair, AB; Singh, K, 2013
)
0.68
"The aim of this work was to evaluate the pharmacokinetic parameters of ciclopirox olamine after the buccal application of mucoadhesive film prepared by the solvent casting method."( Pharmacokinetics of Ciclopirox Olamine after Buccal Administration in Rabbits.
Gajdošová, M; Gajdziok, J; Hauptman, K; Jekl, V; Juřica, J; Knotek, Z; Lukášová, I; Muselík, J; Vetchý, D, 2017
)
1.01
"The pharmacokinetic properties of ciclopirox olamine were studied in New Zealand White rabbits."( Pharmacokinetics of Ciclopirox Olamine after Buccal Administration in Rabbits.
Gajdošová, M; Gajdziok, J; Hauptman, K; Jekl, V; Juřica, J; Knotek, Z; Lukášová, I; Muselík, J; Vetchý, D, 2017
)
1.06

Compound-Compound Interactions

This randomized, evaluator-blind, 3-arm parallel, comparator controlled, multicenter pilot study evaluated the safety and efficacy of ciclopirox nail lacquer topical solution, 8% in combination with oral terbinafine.

ExcerptReferenceRelevance
"This randomized, evaluator-blind, 3-arm parallel, comparator controlled, multicenter pilot study evaluated the safety and efficacy of ciclopirox nail lacquer topical solution, 8% in combination with oral terbinafine for the treatment of moderate to severe toenail onychomycosis (> or =60% disease involvement of target nail and/or lunula/matrix involvement) (N = 73)."( Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study.
Gupta, AK,
)
1.78
"To study the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in onychomycosis."( An open randomized comparative study to test the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in the treatment of onychomycosis.
Garg, AP; Jaiswal, A; Sharma, RP,
)
0.54
"Antifungal effects of iron chelators (lactoferrin, deferoxamine, deferiprone, and ciclopirox) were tested alone and in combination with antifungal drugs against Aspergillus fumigatus B5233 conidia."( Antifungal activities of natural and synthetic iron chelators alone and in combination with azole and polyene antibiotics against Aspergillus fumigatus.
Cruz, AR; Gallin, JI; Huang, CY; Zarember, KA, 2009
)
0.58

Bioavailability

ExcerptReferenceRelevance
"This report presents original methods to assess the bioavailability of an antifungal drug from a varnish preparation in finger nails."( Ciclopirox nail lacquer 8%: in vivo penetration into and through nails and in vitro effect on pig skin.
Ceschin-Roques, CG; Hänel, H; Luc, J; Michel, G; Pruja-Bougaret, SM; Vandermander, J, 1991
)
1.72
"22 h and an intravaginal bioavailability of about 2%."( Pharmacokinetics of ciclopirox olamine after vaginal application to rabbits and patients.
Coppi, G; De Aloysio, D; Girardello, R; Manzardo, S; Silingardi, S, 1993
)
0.61
"One of the pre-requisite for a successful topical antifungal drug indicated for onychomycosis is its bioavailability into the nail unit for achieving fungal eradication and clinical benefit."( Ciclopirox vs amorolfine: in vitro penetration into and permeation through human healthy nails of commercial nail lacquers.
Burgalassi, S; Chetoni, P; Mailland, F; Monti, D; Tampucci, S, 2014
)
1.85
" The bioavailability of CPX olamine formulated as PEO-based MBFs can thus be effectively controlled by inducing the complete dispersion and/or microsegregation and nanocrystallization of CPX olamine in the polymer matrix."( Molecular-Level Control of Ciclopirox Olamine Release from Poly(ethylene oxide)-Based Mucoadhesive Buccal Films: Exploration of Structure-Property Relationships with Solid-State NMR.
Brus, J; Gajdosova, M; Steinhart, M; Urbanova, M; Vetchy, D, 2016
)
0.73
" The oral route of administration for CPX-O is not feasible due to low bioavailability and dose-limiting gastrointestinal toxicities."( Preclinical Pharmacokinetics of Fosciclopirox, a Novel Treatment of Urothelial Cancers, in Rats and Dogs.
Anant, S; Baltezor, MJ; Brinker, AE; Dalton, M; Ham, T; Heppert, K; Jensen, RA; McCulloch, W; McKenna, MJ; Rajewski, L; Ramamoorthy, P; Reed, GA; Schorno, K; Tanol, M; Taylor, JA; Weir, SJ; Wood, R, 2019
)
0.79
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Five patents have been retrieved: four patents on the development of CPX prodrugs to improve the water solubility and bioavailability of CPX, and one patent on the methods of bladder cancer treatment with CPX, CPX-O, or a CPX prodrug."( Reposition of the Fungicide Ciclopirox for Cancer Treatment.
Huang, S; Huang, Z, 2021
)
0.92
" Its clinical utility as an oral anticancer agent, however, is limited by poor oral bioavailability and gastrointestinal toxicity."( Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting the γ-secretase complex.
Anant, S; Baltezor, MJ; Bhattacharyya, S; Brinker, AE; Dalton, M; Dandawate, P; Ham, T; Jensen, RA; McCulloch, W; Ramamoorthy, P; Rangarajan, P; Reed, GA; Standing, D; Tanol, M; Taylor, JA; Weir, SJ; Wood, R; Woolbright, BL, 2021
)
1.24
" Super bioavailability (SUBA) itraconazole was initially not tolerated."( [Recurrent tinea corporis generalisata due to Terbinafine-resistant Trichophyton rubrum strain : Long-term treatment with super bioavailability itraconazole].
Burmester, A; Ebert, A; Monod, M; Nenoff, P; Schaller, M; Stahl, M; Uhrlaß, S, 2023
)
0.91

Dosage Studied

Once-daily dosing of oral ciclopirox olamine was well tolerated in patients with relapsed or refractory hematologic malignancies. A highly sensitive and selective spectrofluorimetric method was developed for the determination of cicLopiroz Olamine in raw material and in dosage forms. Bigels with cic Lox are a promising dosage form for topical use.

ExcerptRelevanceReference
" Following this dosage regimen, side effects did not occur."( Efficacy of ciclopiroxolamine 1% cream in onychomycosis and tinea pedis.
Chuan, MT; Lü, YC; Wu, YC,
)
0.51
" They concern the great uniformity of MICs in pathogenic fungi, their consistency under various test conditions, the importance of the nutrient medium for the level of in vitro activity, and the steepness of dose-response curves."( [Microbiological laboratory studies with ciclopiroxolamine (author's transl)].
Dittmar, W; Grau, W; Raether, W; Schrinner, E; Wagner, WH, 1981
)
0.53
" Firstly, the purpose of the study, the comparator drugs, their dosage regimens and the time frame of the analysis were defined."( Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany.
De Doncker, P; Dubois, DJ; Eggleston, A; Gupta, AK; Haneke, E; Tormans, G; Van Doorslaer, EK; Van Rossem, K, 1996
)
0.29
" The use of combination therapy may be synergistic in terms of efficacy, enabling a reduction in the duration and cumulative dosage of oral therapy."( Ciclopirox nail lacquer solution 8% in the 21st century.
Baran, R; Gupta, AK, 2000
)
1.75
" Combination therapy with an oral antifungal agent may reduce the duration and cumulative dosage of oral therapy."( Ciclopirox nail lacquer: a brush with onychomycosis.
Gupta, AK, 2001
)
1.75
" These agents differ in their dosing regimen, efficacy, adverse events profile, potential for drug interaction, and cost."( Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails.
Amaya, K; Arikian, S; Casciano, J; Doyle, J; Haspel, M; Kahler, K; Shear, N, 2003
)
0.32
"Two simple and sensitive methods are described for the determination of ciclopirox olamine in its pure form and different dosage forms."( Polarographic determination of ciclopirox olamine in pure substance and in different pharmaceutical preparations.
El-Enany, N; Ibrahim, F, 2003
)
0.84
"Oral mucoadhesive tablets belong to modern dosage forms, which allow controlled drug release after buccal application."( [Mucoadhesive tablets for oral administration of ciclopiroxolamine].
Kuna, M; Rabisková, M, 2007
)
0.59
"Transungual delivery of antifungal drugs is hindered by the low permeability of human nail plates, and as such, repeated dosing over a long period of time is necessary for effective treatment."( Iontophoretically enhanced ciclopirox delivery into and across human nail plate.
Hao, J; Li, SK; Smith, KA, 2009
)
0.65
"A highly sensitive and selective spectrofluorimetric method was developed for the determination of ciclopirox olamine in raw material and in dosage forms."( Spectrofluorimetric determination of ciclopirox olamine via ternary complex with Tb(III) and EDTA.
Eid, MI; Fathy, Mel S; Rizk, MS; Walash, MI, 2006
)
0.82
" Forty children aged 1-11 years with clinically diagnosed tinea capitis were randomized to receive selenium sulfide shampoo 1% or ciclopirox shampoo 1% twice a week as adjuncts to an 8-week course of ultramicronized griseofulvin dosed at 10-12 mg/kg/day."( A randomized, double-blind study comparing the efficacy of selenium sulfide shampoo 1% and ciclopirox shampoo 1% as adjunctive treatments for tinea capitis in children.
Barnes-Eley, ML; Chen, C; Dempsey, KK; Dice, JE; Hubbard, TW; Koch, LH; Moskowitz, AB; Williams, JV,
)
0.56
"The nail lacquer containing ciclopirox 8% was equally effective at a weekly dose when compared to the traditional dosing (3/2/1), allowing a more comfortable regimen."( Comparative clinical evaluation of efficacy and safety of a formulation containing ciclopirox 8% in the form of a therapeutic nail lacquer in two different posologies for the treatment of onychomycosis of the toes.
Gomes Neto, A; Nunes, S; Schalka, S,
)
0.65
" The frequent and large dosing of available vaginal CPO creams gives rise to poor compliance amongst females."( Mucoadhesive nanoliposomal formulation for vaginal delivery of an antifungal.
Atmaram, P; Karimunnisa, S, 2013
)
0.39
" Once-daily dosing of oral ciclopirox olamine was well tolerated in patients with relapsed or refractory hematologic malignancies, and further optimization of dosing regimens is warranted in this patient population."( Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies.
Brandwein, JM; Chang, H; Goard, CA; Gronda, M; Gupta, V; Haslam, JL; Heppert, KE; Hogge, DE; Hurren, R; Jitkova, Y; Kasper, J; Minden, MD; Patton, L; Rajewski, LG; Reed, GA; Schimmer, AD; Schorno, K; Schuh, AC; Trudel, S; Webster, DA; Weir, SJ; Yee, KW, 2014
)
1.21
" Retention studies were carried out applying tape stripping method and dosing CO in stratum corneum and in epidermis and dermis."( Development of ciclopirox olamine topical formulations: evaluation of drug release, penetration and cutaneous retention.
Baby, AR; Consiglieri, VO; Kaneko, TM; Pinheiro, VA; Serikaku, D; Velasco, MV, 2015
)
0.77
" Study B: More subjects adhered to amorolfine dosage (81."( Patient-reported outcomes from two randomised studies comparing once-weekly application of amorolfine 5% nail lacquer to other methods of topical treatment in distal and lateral subungual onychomycosis.
Sarkany, M; Schaller, M; Sigurgeirsson, B, 2017
)
0.46
" Thus, bigels with ciclopirox olamine and terbinafine hydrochloride are a promising dosage form for topical use."( Topical antifungal bigels: Formulation, characterization and evaluation.
Briedis, V; Grigonis, A; Ivaskiene, M; Mazurkeviciute, A; Ramanauskiene, K, 2018
)
0.81
"Per-weight dosing regimens of systemic antifungal agents such as terbinafine, itraconazole, and fluconazole are found to be safe in children and are used off-label for the treatment of pediatric onychomycosis with high efficacy."( Onychomycosis in children - review on treatment and management strategies.
Gupta, AK; Piguet, V; Shear, NH; Venkataraman, M, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antibacterial agentA substance (or active part thereof) that kills or slows the growth of bacteria.
antiseborrheicA drug or agent applied to the skin to control seborrhea or seborrheic dermatitis.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
pyridone
cyclic hydroxamic acidA lactam having a hydroxy substituent on the amide nitrogen.
hydroxypyridone antifungal drugAny pyridone which is substituted on the nitrogen by a hydroxy group and which has been used as an antifungal drug.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fumarate hydrataseHomo sapiens (human)Potency6.61900.00308.794948.0869AID1347053
PPM1D proteinHomo sapiens (human)Potency20.82120.00529.466132.9993AID1347411
EWS/FLI fusion proteinHomo sapiens (human)Potency5.97190.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
polyproteinZika virusPotency6.61900.00308.794948.0869AID1347053
Interferon betaHomo sapiens (human)Potency20.82120.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Isocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)Ki50.00000.12001.10673.1700AID1167085
Lysine-specific demethylase 4BHomo sapiens (human)IC50 (µMol)3.80000.20001.22003.8000AID1885255
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Hypoxia-inducible factor 1-alphaHomo sapiens (human)IC50 (µMol)4.50000.00072.46529.2100AID1799545
Multidrug and toxin extrusion protein 1Homo sapiens (human)IC50 (µMol)500.00000.01002.765610.0000AID721754
Deoxyhypusine hydroxylaseHomo sapiens (human)IC50 (µMol)5.00005.00005.00005.0000AID1601772
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (170)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
glyoxylate cycleIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
tricarboxylic acid cycleIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
isocitrate metabolic processIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
2-oxoglutarate metabolic processIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
glutathione metabolic processIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
response to oxidative stressIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
female gonad developmentIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
response to steroid hormoneIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
regulation of phospholipid catabolic processIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
regulation of phospholipid biosynthetic processIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
NADP metabolic processIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
brain developmentLysine-specific demethylase 4BHomo sapiens (human)
chromatin remodelingLysine-specific demethylase 4BHomo sapiens (human)
regulation of gene expressionLysine-specific demethylase 4BHomo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of chemokine-mediated signaling pathwayHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of signaling receptor activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to hypoxiaHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of DNA-templated transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to reactive oxygen speciesHypoxia-inducible factor 1-alphaHomo sapiens (human)
angiogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to hypoxiaHypoxia-inducible factor 1-alphaHomo sapiens (human)
intracellular glucose homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
neural crest cell migrationHypoxia-inducible factor 1-alphaHomo sapiens (human)
epithelial to mesenchymal transitionHypoxia-inducible factor 1-alphaHomo sapiens (human)
embryonic placenta developmentHypoxia-inducible factor 1-alphaHomo sapiens (human)
B-1 B cell homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of endothelial cell proliferationHypoxia-inducible factor 1-alphaHomo sapiens (human)
heart loopingHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of neuroblast proliferationHypoxia-inducible factor 1-alphaHomo sapiens (human)
chondrocyte differentiationHypoxia-inducible factor 1-alphaHomo sapiens (human)
glandular epithelial cell maturationHypoxia-inducible factor 1-alphaHomo sapiens (human)
connective tissue replacement involved in inflammatory response wound healingHypoxia-inducible factor 1-alphaHomo sapiens (human)
outflow tract morphogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
cardiac ventricle morphogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
lactate metabolic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of glycolytic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of DNA-templated transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
intracellular iron ion homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
signal transductionHypoxia-inducible factor 1-alphaHomo sapiens (human)
neuroblast proliferationHypoxia-inducible factor 1-alphaHomo sapiens (human)
lactationHypoxia-inducible factor 1-alphaHomo sapiens (human)
visual learningHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to iron ionHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of gene expressionHypoxia-inducible factor 1-alphaHomo sapiens (human)
vascular endothelial growth factor productionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of vascular endothelial growth factor productionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of gene expressionHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of gene expressionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of epithelial cell migrationHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to muscle activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
axonal transport of mitochondrionHypoxia-inducible factor 1-alphaHomo sapiens (human)
neural fold elevation formationHypoxia-inducible factor 1-alphaHomo sapiens (human)
cerebral cortex developmentHypoxia-inducible factor 1-alphaHomo sapiens (human)
bone mineralizationHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of bone mineralizationHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayHypoxia-inducible factor 1-alphaHomo sapiens (human)
TOR signalingHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of TOR signalingHypoxia-inducible factor 1-alphaHomo sapiens (human)
intracellular oxygen homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of chemokine productionHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of transforming growth factor beta2 productionHypoxia-inducible factor 1-alphaHomo sapiens (human)
collagen metabolic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
cellular response to oxidative stressHypoxia-inducible factor 1-alphaHomo sapiens (human)
embryonic hemopoiesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
insulin secretion involved in cellular response to glucose stimulusHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of insulin secretion involved in cellular response to glucose stimulusHypoxia-inducible factor 1-alphaHomo sapiens (human)
hemoglobin biosynthetic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of erythrocyte differentiationHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of angiogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of growthHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIHypoxia-inducible factor 1-alphaHomo sapiens (human)
muscle cell cellular homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of hormone biosynthetic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
digestive tract morphogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of nitric-oxide synthase activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
neuron apoptotic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
elastin metabolic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
intestinal epithelial cell maturationHypoxia-inducible factor 1-alphaHomo sapiens (human)
epithelial cell differentiation involved in mammary gland alveolus developmentHypoxia-inducible factor 1-alphaHomo sapiens (human)
iris morphogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
retina vasculature development in camera-type eyeHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of thymocyte apoptotic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
cellular response to interleukin-1Hypoxia-inducible factor 1-alphaHomo sapiens (human)
cellular response to hypoxiaHypoxia-inducible factor 1-alphaHomo sapiens (human)
dopaminergic neuron differentiationHypoxia-inducible factor 1-alphaHomo sapiens (human)
mesenchymal cell apoptotic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
hypoxia-inducible factor-1alpha signaling pathwayHypoxia-inducible factor 1-alphaHomo sapiens (human)
cellular response to virusHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of cytokine production involved in inflammatory responseHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of mitophagyHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of miRNA transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of miRNA transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathwayHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of aerobic respirationHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of reactive oxygen species metabolic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of protein neddylationHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of mesenchymal cell apoptotic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of transcription by RNA polymerase IIHypoxia-inducible factor 1-alphaHomo sapiens (human)
xenobiotic transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
organic cation transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
putrescine transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
thiamine transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
amino acid import across plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine import across plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-alpha-amino acid transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
proton transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
peptidyl-lysine modification to peptidyl-hypusineDeoxyhypusine hydroxylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (70)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
magnesium ion bindingIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
isocitrate dehydrogenase (NADP+) activityIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
protein bindingIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
identical protein bindingIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
protein homodimerization activityIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
cadherin bindingIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
NADP bindingIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
NAD bindingIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
histone demethylase activityLysine-specific demethylase 4BHomo sapiens (human)
histone H3K9 demethylase activityLysine-specific demethylase 4BHomo sapiens (human)
metal ion bindingLysine-specific demethylase 4BHomo sapiens (human)
histone H3K36 demethylase activityLysine-specific demethylase 4BHomo sapiens (human)
histone H3K9me2/H3K9me3 demethylase activityLysine-specific demethylase 4BHomo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificHypoxia-inducible factor 1-alphaHomo sapiens (human)
sequence-specific DNA bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificHypoxia-inducible factor 1-alphaHomo sapiens (human)
cis-regulatory region sequence-specific DNA bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription activator activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription repressor activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
transcription coactivator bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificHypoxia-inducible factor 1-alphaHomo sapiens (human)
p53 bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription factor activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
nuclear receptor bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
enzyme bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein kinase bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein domain specific bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
ubiquitin protein ligase bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
histone deacetylase bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein heterodimerization activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
Hsp90 protein bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
E-box bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
transcription regulator activator activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein bindingMultidrug and toxin extrusion protein 1Homo sapiens (human)
organic cation transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-amino acid transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
thiamine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
antiporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
putrescine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
polyspecific organic cation:proton antiporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
iron ion bindingDeoxyhypusine hydroxylaseHomo sapiens (human)
protein bindingDeoxyhypusine hydroxylaseHomo sapiens (human)
deoxyhypusine monooxygenase activityDeoxyhypusine hydroxylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (38)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
extracellular regionIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
cytoplasmIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
peroxisomeIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
peroxisomal matrixIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
cytosolIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
secretory granule lumenIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
extracellular exosomeIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
tertiary granule lumenIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
ficolin-1-rich granule lumenIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
cytosolIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
mitochondrionIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
peroxisomeIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
nucleoplasmLysine-specific demethylase 4BHomo sapiens (human)
chromatinLysine-specific demethylase 4BHomo sapiens (human)
nucleusLysine-specific demethylase 4BHomo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
nucleusHypoxia-inducible factor 1-alphaHomo sapiens (human)
nucleoplasmHypoxia-inducible factor 1-alphaHomo sapiens (human)
cytoplasmHypoxia-inducible factor 1-alphaHomo sapiens (human)
cytosolHypoxia-inducible factor 1-alphaHomo sapiens (human)
nuclear bodyHypoxia-inducible factor 1-alphaHomo sapiens (human)
nuclear speckHypoxia-inducible factor 1-alphaHomo sapiens (human)
motile ciliumHypoxia-inducible factor 1-alphaHomo sapiens (human)
axon cytoplasmHypoxia-inducible factor 1-alphaHomo sapiens (human)
chromatinHypoxia-inducible factor 1-alphaHomo sapiens (human)
euchromatinHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein-containing complexHypoxia-inducible factor 1-alphaHomo sapiens (human)
RNA polymerase II transcription regulator complexHypoxia-inducible factor 1-alphaHomo sapiens (human)
plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
basolateral plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
apical plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
cellular_componentDeoxyhypusine hydroxylaseHomo sapiens (human)
cytosolDeoxyhypusine hydroxylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (111)

Assay IDTitleYearJournalArticle
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1528883Antioxidant activity assessed as trolox equivalent of AAPH radical scavenging activity measured every min for 180 mins by ORAC-FL assay2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Development of Novel
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1528885Solubility of the compound in water incubated for 24 hrs by HPLC analysis2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Development of Novel
AID1339174Inhibition of H2O2-induced mitochondrial metabolic dysfunction in Sprague-Dawley rat primary astrocytes at 0.001 to 10 uM by resazurin-dye based presto blue assay relative to control2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Discovery of a novel series of N-hydroxypyridone derivatives protecting astrocytes against hydrogen peroxide-induced toxicity via improved mitochondrial functionality.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1167085Inhibition of human IDH1 R132H mutant expressed in Escherichia coli BL21-CodonPlus assessed as reduction in NADPH consumption2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID721754Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1473835Stimulation of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1528902Metal chelating activity of the compound assessed as formation of ferric-compound complex by measuring change in color at 60 uM after 15 mins using FeSO4 solution by UV-vis spectrophotometric method2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Development of Novel
AID1884117Antiviral activity against thymidine kinase-deficient ACV-resistant HSV-2 186 TKdeltakpn infected in African green monkey Vero cells assessed as inhibition of viral replication incubated for 1 hr followed by washing with PBS and subsequent treatment with 2022European journal of medicinal chemistry, Aug-05, Volume: 238Synthetic derivatives of the antifungal drug ciclopirox are active against herpes simplex virus 2.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1885255Inhibition of GST-tagged KDM4B (unknown origin) using H3K9(me3)-biotin peptide as substrate incubated for 30 mins and measured after 15 mins by TR-FRET assay2022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Recent Advances with KDM4 Inhibitors and Potential Applications.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1184068Inhibition of IDO1 (unknown origin) using L-tryptophan substrate incubated for 60 mins by HPLC2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID1809907Fungicidal activity against Trichophyton mentagrophytes KCCM60449 at 8 times after 24 hrs by time-kill kinetics assay2021Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
Optimization and Evaluation of Novel Antifungal Agents for the Treatment of Fungal Infection.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1884116Antiviral activity against wild-type HSV-2 186 infected in African green monkey Vero cells assessed as inhibition of viral replication incubated for 1 hr followed by washing with PBS and subsequent treatment with compound for 24 hrs by plaque reduction as2022European journal of medicinal chemistry, Aug-05, Volume: 238Synthetic derivatives of the antifungal drug ciclopirox are active against herpes simplex virus 2.
AID721753Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells at 20 uM after 1.5 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1339173Inhibition of H2O2-induced mitochondrial metabolic dysfunction in Sprague-Dawley rat primary astrocytes by resazurin-dye based presto blue assay2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Discovery of a novel series of N-hydroxypyridone derivatives protecting astrocytes against hydrogen peroxide-induced toxicity via improved mitochondrial functionality.
AID1339176Cytoprotective activity in Sprague-Dawley rat primary astrocytes assessed as inhibition of H2O2-induced cell death at 0.001 to 10 uM by LDH release assay relative to control2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Discovery of a novel series of N-hydroxypyridone derivatives protecting astrocytes against hydrogen peroxide-induced toxicity via improved mitochondrial functionality.
AID678066Inhibition of spore germination of Phytophthora infestans assessed as compound concentration causing 75 to 100% germination inhibition2012Journal of natural products, Jul-27, Volume: 75, Issue:7
Isolactarane and sterpurane sesquiterpenoids from the basidiomycete Phlebia uda.
AID1528897Metal chelating activity of the compound assessed as formation of ferric-compound complex at 60 uM after 15 mins using FeSO4 solution by UV-vis spectrophotometric method2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Development of Novel
AID678067Inhibition of spore germination of Botrytis cinerea assessed as compound concentration causing 75 to 100% germination inhibition2012Journal of natural products, Jul-27, Volume: 75, Issue:7
Isolactarane and sterpurane sesquiterpenoids from the basidiomycete Phlebia uda.
AID266929Antifungal activity against Aspergillus fumigatus2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1339178Cytoprotective activity in Sprague-Dawley rat primary astrocytes assessed as inhibition of H2O2-induced mitochondrial membrane depolarization at 1 uM measured every 5 mins for 2 hrs by TMRM dye based fluorescence assay2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Discovery of a novel series of N-hydroxypyridone derivatives protecting astrocytes against hydrogen peroxide-induced toxicity via improved mitochondrial functionality.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID678064Inhibition of spore germination of Fusarium graminearum assessed as compound concentration causing 75 to 100% germination inhibition2012Journal of natural products, Jul-27, Volume: 75, Issue:7
Isolactarane and sterpurane sesquiterpenoids from the basidiomycete Phlebia uda.
AID1884113Selectivity index, ratio of CC50 for cytotoxicity against African green monkey Vero cells to EC50 for antiviral activity against HSV-2 infected in African green monkey Vero cells2022European journal of medicinal chemistry, Aug-05, Volume: 238Synthetic derivatives of the antifungal drug ciclopirox are active against herpes simplex virus 2.
AID1809906Fungicidal activity against Trichophyton rubrum KCCM60450 at 8 times after 24 hrs by time-kill kinetics assay2021Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
Optimization and Evaluation of Novel Antifungal Agents for the Treatment of Fungal Infection.
AID1528873Neuroprotective activity against oxygen-glucose deprivation-induced toxicity in human SH-SY5Y cells assessed as cell viability at 1 uM preincubated for 2 hrs followed by OGD-challenge and measured after 24 hrs by MTT assay (Rvb = 54.92 +/- 2.12%)2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Development of Novel
AID266925Antifungal activity against Trichophyton rubrum2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis.
AID1184074Solubility of the compound in pH 6.5 phosphate buffer containing 5% DMSO2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID266926Antifungal activity against Trichophyton mentagrophytes2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis.
AID1884111Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 24 hrs by MTS assay2022European journal of medicinal chemistry, Aug-05, Volume: 238Synthetic derivatives of the antifungal drug ciclopirox are active against herpes simplex virus 2.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678065Inhibition of spore germination of Magnaporthe grisea assessed as compound concentration causing 75 to 100% germination inhibition2012Journal of natural products, Jul-27, Volume: 75, Issue:7
Isolactarane and sterpurane sesquiterpenoids from the basidiomycete Phlebia uda.
AID1884112Cytotoxicity against human HepDES19 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay2022European journal of medicinal chemistry, Aug-05, Volume: 238Synthetic derivatives of the antifungal drug ciclopirox are active against herpes simplex virus 2.
AID266928Antifungal activity against Cryptococcus neoformans2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis.
AID1528896Metal chelating activity of the compound assessed as formation of ferric-compound complex at 60 uM after 15 mins using ammonium iron citrate solution by UV-vis spectrophotometric method2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Development of Novel
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1884106Antiviral activity against HSV-2 infected in African green monkey Vero cells assessed as inhibition of viral replication by measuring log suppression of virus-induced cytopathic effect at 1 uM incubated for 1 hr followed by washing with PBS and subsequent2022European journal of medicinal chemistry, Aug-05, Volume: 238Synthetic derivatives of the antifungal drug ciclopirox are active against herpes simplex virus 2.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1528899Metal chelating activity of the compound assessed as formation of ferrous-compound complex at 60 uM after 15 mins using ammonium iron(II) sulfate solution by UV-vis spectrophotometric method2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Development of Novel
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID275825Antifungal activity against Fusarium verticillioides Nirenberg (Sacc.) by agar diffusion method at 50 ug2007Journal of natural products, Jan, Volume: 70, Issue:1
Antifungal acylcyclopentenediones from fruiting bodies of Hygrophorus chrysodon.
AID558870Antifungal activity against Aspergillus fumigatus B5233 conidia after 16 hrs by fluorescence-based microplate assay at pH 7.22009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Antifungal activities of natural and synthetic iron chelators alone and in combination with azole and polyene antibiotics against Aspergillus fumigatus.
AID1884108Antiviral activity against HSV-1 infected in African green monkey Vero cells assessed as inhibition of viral replication by measuring log suppression of virus-induced cytopathic effect at 1 uM incubated for 1 hr followed by washing with PBS and subsequent2022European journal of medicinal chemistry, Aug-05, Volume: 238Synthetic derivatives of the antifungal drug ciclopirox are active against herpes simplex virus 2.
AID266927Antifungal activity against Candida albicans2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis.
AID1884114Selectivity index, ratio of CC50 for cytotoxicity against human HepDES19 cells to EC50 for antiviral activity against HSV-2 infected in African green monkey Vero cells2022European journal of medicinal chemistry, Aug-05, Volume: 238Synthetic derivatives of the antifungal drug ciclopirox are active against herpes simplex virus 2.
AID1528900Metal chelating activity of the compound assessed as formation of ferric-compound complex at 60 uM after 15 mins using FeCl3 solution by UV-vis spectrophotometric method2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Development of Novel
AID1339175Cytoprotective activity in Sprague-Dawley rat primary astrocytes assessed as inhibition of H2O2-induced cell death by LDH release assay2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Discovery of a novel series of N-hydroxypyridone derivatives protecting astrocytes against hydrogen peroxide-induced toxicity via improved mitochondrial functionality.
AID1528898Metal chelating activity of the compound assessed as formation of ferric-compound complex at 60 uM after 15 mins using ammonium iron sulfate solution by UV-vis spectrophotometric method2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Development of Novel
AID1601772Inhibition of DOHH (unknown origin)2019European journal of medicinal chemistry, Mar-01, Volume: 165Medicinal chemistry of metal chelating fragments in metalloenzyme active sites: A perspective.
AID1884107Antiviral activity against HSV-1 infected in African green monkey Vero cells assessed as inhibition of viral replication by measuring log suppression of virus-induced cytopathic effect at 5 uM incubated for 1 hr followed by washing with PBS and subsequent2022European journal of medicinal chemistry, Aug-05, Volume: 238Synthetic derivatives of the antifungal drug ciclopirox are active against herpes simplex virus 2.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1184075Inhibition of IDO1 (unknown origin) at highest soluble concentration using L-tryptophan substrate incubated for 60 mins by HPLC2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID1884109Antiviral activity against HSV-1 infected in African green monkey Vero cells assessed as inhibition of viral replication incubated for 1 hr followed by washing with PBS and subsequent treatment with compound for 24 hrs by plaque reduction assay2022European journal of medicinal chemistry, Aug-05, Volume: 238Synthetic derivatives of the antifungal drug ciclopirox are active against herpes simplex virus 2.
AID1884105Antiviral activity against HSV-2 infected in African green monkey Vero cells assessed as inhibition of viral replication by measuring log suppression of virus-induced cytopathic effect at 5 uM incubated for 1 hr followed by washing with PBS and subsequent2022European journal of medicinal chemistry, Aug-05, Volume: 238Synthetic derivatives of the antifungal drug ciclopirox are active against herpes simplex virus 2.
AID1528901Metal chelating activity of the compound assessed as formation of ferric-compound complex by measuring change in color at 60 uM after 15 mins using ammonium iron citrate solution by UV-vis spectrophotometric method2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Development of Novel
AID1809952Ex vivo antifungal activity against Trichophyton rubrum KCCM60450 infected in human nail assessed as reduction in ATP level at 10 % w/w after 24 hrs2021Journal of medicinal chemistry, 11-11, Volume: 64, Issue:21
Optimization and Evaluation of Novel Antifungal Agents for the Treatment of Fungal Infection.
AID1528884Permeability of the compound incubated for 10 hrs by PAMPA2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Development of Novel
AID1884110Antiviral activity against HSV-2 infected in African green monkey Vero cells assessed as inhibition of viral replication incubated for 1 hr followed by washing with PBS and subsequent treatment with compound for 24 hrs by plaque reduction assay2022European journal of medicinal chemistry, Aug-05, Volume: 238Synthetic derivatives of the antifungal drug ciclopirox are active against herpes simplex virus 2.
AID1528879Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Development of Novel
AID1885256Antiproliferative activity against human neuroblastoma cells after 3 days by PrestoBlue assay2022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Recent Advances with KDM4 Inhibitors and Potential Applications.
AID1528874Neuroprotective activity against oxygen-glucose deprivation-induced toxicity in human SH-SY5Y cells assessed as cell viability at 10 uM preincubated for 2 hrs followed by OGD-challenge and measured after 24 hrs by MTT assay (Rvb = 54.92 +/- 2.12%)2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Development of Novel
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1799545Enzyme Inhibition Assay from Article 10.1016/j.chembiol.2010.03.008: \\Utilization of an in vivo reporter for high throughput identification of branched small molecule regulators of hypoxic adaptation.\\2010Chemistry & biology, Apr-23, Volume: 17, Issue:4
Utilization of an in vivo reporter for high throughput identification of branched small molecule regulators of hypoxic adaptation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (428)

TimeframeStudies, This Drug (%)All Drugs %
pre-199046 (10.75)18.7374
1990's43 (10.05)18.2507
2000's134 (31.31)29.6817
2010's150 (35.05)24.3611
2020's55 (12.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 62.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index62.51 (24.57)
Research Supply Index6.31 (2.92)
Research Growth Index4.84 (4.65)
Search Engine Demand Index187.19 (26.88)
Search Engine Supply Index3.50 (0.95)

This Compound (62.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials76 (16.14%)5.53%
Reviews50 (10.62%)6.00%
Case Studies47 (9.98%)4.05%
Observational0 (0.00%)0.25%
Other298 (63.27%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (17)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Clinical, Laboratorial and Quality of Life Trial to Evaluate the Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea. [NCT01139749]Phase 450 participants (Anticipated)Interventional2011-10-31Recruiting
A Phase I, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety and Pharmacokinetics of ATL-001 (Ciclopirox Olamine) in Healthy Volunteers [NCT05647343]Phase 132 participants (Anticipated)Interventional2023-03-27Recruiting
The Efficacy of CELEXT07 in the Treatment of Toenail Onychomycosis: a Phase 2, Randomized, Double-blind Study [NCT02644551]Phase 2120 participants (Anticipated)Interventional2016-11-30Recruiting
Phase 1 Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy [NCT00990587]Phase 120 participants (Actual)Interventional2009-10-31Completed
A Multicentre, Randomized, Controlled Study of the Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer Alone for the Trea [NCT01014637]Phase 4260 participants (Anticipated)Interventional2009-08-31Recruiting
A Prospective, Double-blind, Placebo-controlled Trial of Topical Penlac Nail Lacquer for Therapy of Onychomycosis in Children [NCT01419847]Phase 440 participants (Actual)Interventional2002-03-31Completed
Phase 3 : Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis on Adult Face [NCT02004860]Phase 3120 participants (Actual)Interventional2014-01-31Completed
Study for the Assessment of Safety and Efficacy of Ciclopirox Olamine Cream in 3 Months to 10 Years Old Children With Dermatomycoses [NCT01646580]Phase 421 participants (Actual)Interventional2008-10-31Terminated(stopped due to Low recruitment rate. with the final sample primary endpoint could be assessed.)
A Multi-centre, Randomized, Two-armed, Parallel Group and Evaluator-blinded Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO) [NCT02866032]Phase 3452 participants (Actual)Interventional2016-09-30Completed
A Double-blind, Randomized, Parallel-group, Vehicle-controlled, Multi-center Study to Evaluate the Safety and Clinical Equivalence of a Generic Ciclopirox Olamine Topical Suspension to Reference Ciclopirox Topical Suspension 0.77% in the Treatment of Tine [NCT00804193]553 participants (Actual)Interventional2004-06-30Completed
A Double-blind, Randomized, Parallel-group, Vehicle-controlled, Multi-center Study to Evaluate the Safety and Clinical Equivalence of a Generic Ciclopirox Olamine Cream to Ciclopirox Cream 0.77% in the Treatment of Tinea Pedis [NCT00802672]Phase 3561 participants (Actual)Interventional2003-12-31Completed
Diode Laser and Photodynamic Therapy Versus Ciclopirox Hydroxypropyl Chitosan. Randomised Controlled Clinical Trial. [NCT05809297]Phase 426 participants (Anticipated)Interventional2023-09-01Not yet recruiting
Study Efficacy and Safety in Comparative Use of Investigational Product Adjuvant Treatment in Onychomycosis [NCT02961634]Phase 346 participants (Anticipated)Interventional2017-04-30Not yet recruiting
A Randomized, Double-Blinded, Placebo-Controlled Study Observing the Efficacy of Selenium Sulfide 1% Shampoo, Ketoconazole 2% Shampoo, and Ciclopirox 1% Shampoo as Adjunctive Treatments for Tinea Capitis in Children [NCT00127868]47 participants (Actual)Interventional2005-03-31Completed
Chemoprevention of Cancer in the Lower Female Genital Tract: The Antineoplastic Activity of the Fungicide Ciclopirox. [NCT00382330]0 participants (Actual)InterventionalWithdrawn
Subject Adherence and Satisfaction for Treatment of Onychomycosis With Loceryl Nail Lacquer 5% Versus Ciclopirox Nail Lacquer [NCT02679911]Phase 420 participants (Actual)Interventional2015-09-30Completed
Pilot Study on the Evaluation of the Efficacy, Tolerability and Safety of Topical and Oral Antifungals in the Treatment of Onychomycosis and Creation of a Library of Dermatological Clinical Isolates [NCT05482763]200 participants (Anticipated)Observational [Patient Registry]2022-07-20Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00802672 (3) [back to overview]Proportion of Subjects in Each Treatment Group With Therapeutic Success
NCT00802672 (3) [back to overview]Proportion of Subjects With Clinical Cure
NCT00802672 (3) [back to overview]Proportion of Subjects With Mycological Cure
NCT00804193 (3) [back to overview]Proportion of Subjects in Each Treatment Group With Therapeutic Success
NCT00804193 (3) [back to overview]Proportion of Subjects With Clinical Cure
NCT00804193 (3) [back to overview]Proportion of Subjects With Mycological Cure
NCT02679911 (2) [back to overview]"Percent of in Label Adherent Subjects"
NCT02679911 (2) [back to overview]Percent of Subjects Satisfied to Very Satisfied With Each Study Treatment at Week 12

Proportion of Subjects in Each Treatment Group With Therapeutic Success

Both Mycological Cure (KOH wet mount negative and fungal culture negative) and Clinical Cure were required to achieve Therapeutic Success (NCT00802672)
Timeframe: 6 weeks

Interventionparticipants (Number)
Test Product70
Reference Product95
Vehicle Product3

[back to top]

Proportion of Subjects With Clinical Cure

Clinical Cure was defined as a signs and symptoms score of <1 for erythema; <1 for scaling; and 0 for pruritus, maceration, fissuring/cracking, and burning/stinging; as well as an assessment that no additional antifungal therapy was required to treat the subject's current episode of tinea pedis (NCT00802672)
Timeframe: 6 weeks

Interventionparticipants (Number)
Test Product82
Reference Product106
Vehicle Product9

[back to top]

Proportion of Subjects With Mycological Cure

Mycological Cure (KOH wet mount negative and fungal culture negative (NCT00802672)
Timeframe: 6 weeks

Interventionparticipants (Number)
Test Product107
Reference Product133
Vehicle Product9

[back to top]

Proportion of Subjects in Each Treatment Group With Therapeutic Success

Therapeutic success was defined as having both Mycological Cure (potassium hydroxide [KOH] wet mount negative and fungal culture negative) and Clinical Cure (NCT00804193)
Timeframe: 6 weeks

Interventionparticipants (Number)
Test Product93
Reference Product88
Vehicle Product7

[back to top]

Proportion of Subjects With Clinical Cure

Clinical Cure was defined as a signs and symptoms score of <1 for erythema; <1 for scaling; and 0 for pruritus, maceration, fissuring/cracking, and burning/stinging; as well as an assessment that no additional antifungal therapy was required to treat the subject's current episode of tinea pedis (NCT00804193)
Timeframe: 6 weeks

Interventionparticipants (Number)
Test Product81
Reference Product96
Vehicle Product22

[back to top]

Proportion of Subjects With Mycological Cure

Potassium hydroxide [KOH] wet mount negative and fungal culture negative (NCT00804193)
Timeframe: 6 weeks

Interventionparticipants (Number)
Test Product119
Reference Product127
Vehicle Product18

[back to top]

"Percent of in Label Adherent Subjects"

Percent of subjects having applied both treatments as instructed per labeling (once a week for Loceryl NL and once a day for Ciclopirox after 2 weeks) (NCT02679911)
Timeframe: Week 12

Interventionpercentage of participants (Number)
Loceryl NL85
Ciclopirox NL60

[back to top]

Percent of Subjects Satisfied to Very Satisfied With Each Study Treatment at Week 12

Percent of subjects satisfied to very satisfied with both treatments (Loceryl nail lacquer and/or Ciclopirox nail lacquer) at week 12 (NCT02679911)
Timeframe: Week 12

Interventionpercentage of participants (Number)
Loceryl NL60
Ciclopirox NL60

[back to top]